Surgivet advisor

The experimental group (E) comprised 87 dogs which were diagnosed with periodontal disease. They were examined for dental disorders because of the following symptoms: food intake disorders, foetor ex ore, gum redness, swelling and bleeding, purulent exudate, erosions and ulceration on the mucosa, and the presence of dental calculus.
Physical dental examination, periodontal examination and swabbing for microbiological tests were performed on the dogs under general anaesthesia before performing cavity cleaning, as part of the treatment of the periodontal disease. The anaesthesia regimen presented below was used for each patient. The premedication was xylazine (Sedazin; Biowet Puławy, Poland) at a dose of 2 mg/kg body weight (b.w.). After 15 min, the patient had an intravenous line inserted and received ketamine (Vetaketam; VetAgro, Lublin, Poland) at a dose of 8 mg/kg b.w., combined at a 1:1 ratio with diazepam (Relanium; Polfa, Warsaw, Poland) at a dose of 0.5 mg/kg b.w. (administered proportionately to the effect seen). Next, the patient was intubated, and a device monitoring vital signs (SurgiVet Advisor, Smiths Medical, Dublin, OH, USA) was connected. In order to maintain anaesthesia, inhalation (Matrx VMS Plus; Midmark Animal Health, Versailles, OH, USA) was used of a mixture of oxygen and isoflurane at a concentration of 2% (Aerrane; Baxter, Deerfield, IL, USA).

Anesthesia was initiated with an intramuscular injection of 20 mg/kg ketamine (Fort Dodge Animal Health, Overland Park, KS, Cat# NDC 59390-198-50). An endotracheal tube with 0.5–3% isoflurane (MWI Supply, Boise, ID, Cat# 502017) was used to maintain the animal under anesthesia. The animal was placed on a heating pad and secured into a stereotactic frame (Stoelting, Wood Dale, IL, Cat# 51600). Heart rate, respiration, and temperature were monitored throughout the procedure using a SurgiVet Advisor (Smiths Medical, Dublin, OH). Under sterile conditions, a midline incision over the skull was made, and two burr holes were drilled through the cranium at the two injection sites. 2.5 × 10⁸ vp of HC-Ad-TetOn-Ftl3L were injected by Hamilton syringe (Hamilton, Reno, NV, Cat# 7635-01) at four sites in the brain, for a total of 1 × 10⁹ vp. The four stereotactic injection sites, with respect to the bregma, were 5.0 mm anterior, 6.0 mm lateral, 8.0 ventral; 5.0 mm anterior, 6.0 mm lateral, 6.0 mm ventral; 5.0 mm anterior, 8.0 mm lateral, 8.0 mm ventral; and 5.0 mm anterior, 8.0 mm lateral, 6.0 mm ventral. At each site, the vector was slowly injected over a period of 2 minutes, with a 3-minute waiting period between each injection.